Soft Tissue Sarcoma (STS) with Lung Metastases Pipeline Development Activities, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

 Breaking News
  • No posts were found

Soft Tissue Sarcoma (STS) with Lung Metastases Pipeline Development Activities, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Soft Tissue Sarcoma (STS) with Lung Metastases Pipeline Development Activities, Market Trends, Leading Companies, Emerging Drugs, and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Soft Tissue Sarcoma (STS) with Lung Metastases Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Soft Tissue Sarcoma (STS) with Lung Metastases Market Size and Share in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Soft tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels, and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas).

Metastasectomy and/or chemotherapy are the most common treatments offered to patients with metastatic sarcoma. Pulmonary metastasectomy, either video-assisted or through a formal thoracotomy, has been shown to increase overall survival in select populations of both osseous and soft tissue sarcoma patients.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market

The Soft Tissue Sarcoma (STS) with Lung Metastases Market Research Report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted Soft Tissue Sarcoma (STS) with Lung Metastases market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current STS with Lung Metastases treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Soft Tissue Sarcoma (STS) with Lung Metastases Market

Soft Tissue Sarcoma (STS) with Lung Metastases Market Key Facts

  • As per the study conducted by Digesu et al. (2016), sarcoma comprises a heterogeneous group of histologic subtypes with a propensity to metastasize to the lungs. Isolated pulmonary metastases occur in as many as 20% of patients diagnosed with soft tissue sarcoma and as many as 40% in those with primary bone sarcoma.

  • According to the study conducted by Lindsay et al. (2018), soft tissue and bone sarcomas represent less than 1% of all malignancies diagnosed in the United States annually. The most common site of metastasis is the lung, with metastatic pulmonary disease occurring in 19–50% of patients.

  • According to a study conducted by Reza et al. (2014), approximately 20–40% of patients with sarcoma develop pulmonary metastases. Unlike many epithelial cancers, sarcomas very often spread only to the Lungs.

  • According to a study conducted by Lindwer et al. (2018), there were slightly more males (53.4%) patients with lung lesions only, as compared to females (46.6%).

Key Benefits of Soft Tissue Sarcoma (STS) with Lung Metastases Market Report

  • STS with Lung Metastases market report provides an in-depth analysis of Soft Tissue Sarcoma (STS) with Lung Metastases Market Size, Share, Trend, and Epidemiology Forecast till 2030 in the seven major markets (i.e. the United States, EU5 (Germany, Italy, Spain, France, and the UK) and Japan.

  • The report will help in developing business strategies by understanding the Soft Tissue Sarcoma (STS) with Lung Metastases Market Trends, recent developments, key players, and future market competition that will shape and drive the market growth in the upcoming years.

  • The market report covers the STS with Lung Metastases current treatment practices, emerging drugs, market share of the individual therapies in the seven major markets.

  • The report provides a detailed assessment of the STS with Lung Metastases market in terms of market drivers & barriers, unmet needs, market opportunities, patient population, detailed comparative analysis of pipeline products including clinical and non-clinical stage products, and other factors. 

Soft Tissue Sarcoma (STS) with Lung Metastases Market 

Soft Tissue Sarcoma (STS) with Lung Metastases market size is expected to increase during the study period owing to the increased awareness of this unique histology and development of drugs that are specific to STS with lung metastasis. These factors, along with the expected launch of emerging therapies, will boost the market growth.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted STS with Lung Metastases market size and share by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers, and demand for better technology.

The report gives a thorough detail of the STS with Lung Metastases market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

Soft Tissue Sarcoma (STS) with Lung Metastases Epidemiology

The epidemiology section covers insights about the historical and current Soft Tissue Sarcoma (STS) with Lung Metastases patient pool and forecasted trends for every seven major countries from 2017 to 2030. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Soft Tissue Sarcoma (STS) with Lung Metastases Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the STS with Lung Metastases market or expected to get launched in the market during the study period. The analysis covers Soft Tissue Sarcoma with Lung Metastases market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the STS with Lung Metastases Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the Soft Tissue Sarcoma (STS) with Lung Metastases market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for Soft Tissue Sarcoma with Lung Metastases emerging therapies.

Request for Sample @ Soft Tissue Sarcoma (STS) with Lung Metastases Therapeutics Market Assessment

The dynamics of the soft tissue sarcoma with lung metastasis market are anticipated to change in the coming years owing to the rise in healthcare spending across the world. Key players, such as Moleculin Biotech are involved in developing a therapy for soft tissue sarcoma with lung metastasis.

Annamycin, which is being investigated by Moleculin Biotech, is a unique next-generation liposome formulated anthracycline (also referred to in the literature as “L-Annamycin”). It has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines.

The soft tissue sarcoma with lung metastasis pipeline augurs hope for a better treatment pattern in the market in the upcoming years. The current scenario also anticipates a positive shift in the market during the study period.

Table of Content

1. Key Insights

2. Executive Summary 

3. Soft Tissue Sarcoma (STS) with Lung Metastases Competitive Intelligence Analysis

4. Soft Tissue Sarcoma (STS) with Lung Metastases Market Overview at a Glance

5. Soft Tissue Sarcoma (STS) with Lung Metastases Disease Background and Overview

6. Soft Tissue Sarcoma (STS) with Lung Metastases Patient Journey

7. Soft Tissue Sarcoma (STS) with Lung Metastases Epidemiology and Patient Population

8. Soft Tissue Sarcoma (STS) with Lung Metastases Treatment Algorithm, Current Treatment, and Medical Practices

9. Soft Tissue Sarcoma (STS) with Lung Metastases Unmet Needs

10. Key Endpoints of Soft Tissue Sarcoma (STS) with Lung Metastases Treatment

11. Soft Tissue Sarcoma (STS) with Lung Metastases Marketed Products

12. Soft Tissue Sarcoma (STS) with Lung Metastases Emerging Therapies

13. Soft Tissue Sarcoma (STS) with Lung Metastases Seven Major Market Analysis

14. Attribute Analysis

15. Soft Tissue Sarcoma (STS) with Lung Metastases Market Outlook (7 major markets)

16. Soft Tissue Sarcoma (STS) with Lung Metastases Access and Reimbursement Overview

17. KOL Views on the Soft Tissue Sarcoma (STS) with Lung Metastases Market.

18. Soft Tissue Sarcoma (STS) with Lung Metastases Market Drivers

19. Soft Tissue Sarcoma (STS) with Lung Metastases Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Get FREE sample copy at: https://www.delveinsight.com/sample-request/soft-tissue-sarcoma-with-lung-metastases-market

Latest Healthcare Blogs

JAK Inhibitors Market

As per the DelveInsight, JAK Inhibitors Pipeline is expected to be fuelled by rising prescription demand, however side effects, safety issues, regulatory clearances, and labeling restrictions are the key concerns hampering their growth. Currently, some of the key companies investing in the JAK Inhibitors Portfolio to advance the market share includes Eli Lilly and Company, Astellas Pharma US, Pfizer, Baxter International Inc., Novartis, AbbVie, Sierra Oncology, CTI BioPharma, Incyte, and others.

Diabetic Macular Edema Therapy Market

Worldwide several companies are involved in the development of new pharmacological therapies to target the underlying biochemical pathways that trigger DME due to the limitations of current treatments. At present, the key Diabetic Macular Edema Market Companies actively involved in the therapeutics development include Roche, Novartis, Adverum Biotechnologies, Graybug Vision, KalVista Pharmaceuticals, Ocuphire Pharma, Oxurion, YD Life Science, among others. 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/atlantanewsonlin/public_html/news.augustaheadlines.com/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Categories